Sean Maduck - 01 Sep 2023 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Role
Officer
Signature
/s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck
Issuer symbol
CORT
Transactions as of
01 Sep 2023
Net transactions value
+$15,094
Form type
4
Filing time
06 Sep 2023, 18:06:59 UTC
Previous filing
19 Jul 2023
Next filing
20 Sep 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CORT Common Stock Award $15,094 +456 +0.63% $33.10 73,154 01 Sep 2023 Direct F1, F2, F3
transaction CORT Common Stock Award $0 +456 +0.62% $0.000000 73,610 01 Sep 2023 Direct F3, F4
holding CORT Common Stock 10,000 01 Sep 2023 See Footnote F5
holding CORT Common Stock 10,000 01 Sep 2023 See Footnote F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on September 1, 2023.
F2 In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
F3 Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, and 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F4 Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
F5 Represents the shares held by Duckhill Capital, LLC of which the reporting person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
F6 Represents the shares held by Sean and Molly Maduck Living Trust of which the reporting person is a co-trustee.

Remarks:

President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.